As healthcare costs continue to climb, large employers across the United States are sounding the alarm on affordability and transparency as their top concerns when it comes to providing health benefits to employees. According to recent data from the Purchaser Business Group on Health (PBGH), a coalition representing major U.S. Employers, rising medical expenses remain the foremost challenge for its so-called “jumbo” members—companies each employing tens of thousands of workers nationwide.
The findings underscore a growing strain on corporate health benefit strategies, particularly as inflation, prescription drug pricing and hospital consolidation continue to pressure budgets. For HR leaders and benefits managers, the dual challenge of controlling costs while maintaining meaningful coverage has become a defining issue in workplace wellness and talent retention.
PBGH’s latest survey, conducted among its member organizations that collectively cover over 15 million lives, identified healthcare affordability as the primary concern for 89% of respondents. Close behind were demands for greater pricing transparency from providers and pharmacies, cited by 82% of jumbo employers as a critical need to effectively manage plan spending.
“Employers are no longer passive purchasers of health benefits—they’re actively seeking ways to bend the cost curve,” said a PBGH spokesperson in a statement reviewed by World Today Journal. “What we’re seeing is a clear demand for actionable data, fair pricing, and system-level reforms that empower large purchasers to make smarter decisions for their workforce.”
The emphasis on transparency reflects a broader shift in how corporations approach healthcare procurement. With little visibility into negotiated rates between insurers and hospitals, many employers struggle to assess whether they are paying fair market prices for services. This lack of clarity complicates efforts to implement reference-based pricing, narrow networks, or direct contracting models—strategies some companies have adopted to gain more control over spending.
In response, federal initiatives such as the Transparency in Coverage rule, which took effect in phases beginning in 2022, aim to require health plans and insurers to disclose pricing information for covered items and services. While the rule has faced legal challenges and delays, PBGH members have expressed cautious optimism that improved access to machine-readable files could eventually support better benchmarking and negotiation tactics.
Beyond cost and clarity, PBGH’s data also highlighted mental health access and chronic disease management as growing priorities. Nearly three-quarters of jumbo employers reported increasing investment in behavioral health programs, citing rising utilization and employee demand. Similarly, programs targeting diabetes, hypertension, and obesity were noted as key areas where preventive care could yield long-term savings.
These trends align with broader national patterns. The Kaiser Family Foundation’s 2023 Employer Health Benefits Survey found that average annual premiums for employer-sponsored family coverage reached $24,000, with workers contributing over $6,000 on average—a figure that has risen significantly over the past decade. At the same time, out-of-pocket costs continue to climb, placing additional financial strain on households even among those with employer-sponsored insurance.
For large employers, the stakes extend beyond balance sheets. Health benefits are a core component of employee value propositions, influencing recruitment, morale, and productivity. When workers face high deductibles or surprise bills, dissatisfaction can grow—potentially undermining the very purpose of offering comprehensive coverage.
To address these concerns, some PBGH members are exploring innovative models such as accountable care organizations (ACOs), bundled payments, and direct primary care contracts. Others are leveraging their scale to partner with transparent pharmacy benefit managers or negotiate directly with high-performing health systems. A growing number are also investing in care navigation tools to help employees make informed choices about where and how to seek care.
Still, systemic barriers remain. Hospital market consolidation has limited competition in many regions, reducing employers’ leverage in negotiations. Patent protections and lack of generic alternatives continue to drive high costs for specialty drugs, particularly in areas like oncology and immunology. And while transparency rules hold promise, their real-world impact depends on enforcement, usability, and the willingness of stakeholders to engage in good-faith negotiation.
Looking ahead, PBGH plans to continue advocating for policy changes that support employer purchasing power, including reforms to antitrust enforcement in healthcare and greater alignment between quality metrics and payment systems. The group also emphasized the importance of multi-stakeholder collaboration, noting that sustainable solutions will require input from providers, insurers, policymakers, and patients alike.
As the next open enrollment season approaches, many jumbo employers are reviewing their benefit designs with a sharper focus on value—not just cost. The goal, benefits leaders say, is not to reduce coverage but to ensure that every dollar spent delivers measurable improvements in health outcomes and employee satisfaction.
For updates on federal healthcare transparency initiatives and employer-led efforts to improve affordability, readers can refer to official resources from the Centers for Medicare & Medicaid Services (Centers for Medicare & Medicaid Services) and the Purchaser Business Group on Health (Purchaser Business Group on Health).
World Today Journal will continue to monitor developments in employer-sponsored healthcare and their implications for workers, businesses, and the broader U.S. Health system.
Have insights or experiences with employer health benefits? Share your thoughts in the comments below or join the conversation on social media using #HealthAtWork.